Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye scans could reveal how MS drug works in real time

NCT ID NCT06864936

Recruiting now Knowledge-focused Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 25 times

Summary

This study tests whether a special eye scan (OCT) can detect immune cell changes in people with relapsing-remitting multiple sclerosis (MS) who are starting the drug ublituximab (Briumvi). Researchers will compare 15 patients starting ublituximab with 15 stable MS patients not on B-cell therapies. The goal is to find new imaging markers that show how well the treatment is working, without needing invasive tests.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) - RELAPSING-REMITTING are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Maryland, Baltimore

    RECRUITING

    Baltimore, Maryland, 21201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS (MS) - RELAPSING-REMITTING